FDA Approves First-Line Treatment for NSCLC with PD-L1 Biomarker

2019-04-12T17:39:26+00:00April 12th, 2019|Hot Topics, News|

On April 11, the U.S. Food and Drug Administration approved pembrolizumab (KEYTRUDA) as a first-line treatment for patients with advanced NSCLC who have a score of 1% or higher on the PD-L1 biomarker test. The approval was based on KEYNOTE-042 trial which demonstrated statistically significant OS improvements for those randomized to pembrolizumab compared with chemotherapy. Click here to read the full press release.